KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, presented data for its lead oral drug candidate, KVD900, in development for on-demand treatment of hereditary angioedema (HAE), at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Scientific Meeting. Data presentations included new data from the Phase 2 trial highlighting rapid suppression of plasma kallikrein activity after KVD900 administration and its relationship with symptomatic relief.
“These data from our phase 2 trial in on-demand use for HAE attacks show that oral KVD900 is quickly absorbed, leading to rapid, near-complete suppression of plasma kallikrein activity, a key mediator of HAE attacks,” said Andrew Crockett, Chief Executive Officer of KalVista. “We believe that this rapid absorption followed by rapid suppression of plasma kallikrein activity is the basis for the early symptom relief we observed in the trial.”
-
KVD900 was rapidly absorbed, reaching maximum plasma concentrations within 1 hour
-
Plasma kallikrein activity was >80% inhibited within 15 minutes with near-complete inhibition (>95%) observed within 1 hour
-
A significantly shorter median time (1.6 hrs.) to symptom relief was observed in patients receiving KDV900 compared with placebo (9 hrs.)
Poster Title: Agreement of Patient Global Impression of Change (PGI-C) with Attack Resolution or Use of Rescue Mediation in Patients with Hereditary Angioedema
-
113 HAE attacks were treated in a blinded manner with either KVD900 or placebo
-
Symptom relief, as captured by improvement on the PGI-C, occurred in 72% of attacks within 24 hours, and among those only 16% of HAE attacks were associated with use of rescue medication, while approximately 60% achieved complete attack resolution without use of rescue
-
Conversely, for the 28% of attacks were symptom relief was not achieved, 66% were associated with use of rescue medication and less than 4% achieved complete attack resolution without use of rescue
-
PGI-C is an effective tool to monitor attack symptoms may be an early predictor of attack resolution in patients with HAE